THE SGLT2 INHIBITOR CANAGLIFLOZIN SHOWN TO BE SUPERIOR COMPARED WITH GLIMEPIRIDE AS ADD ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES

Idris Iskandar

首页> 外文期刊>Diabetes, obesity & metabolism >THE SGLT2 INHIBITOR CANAGLIFLOZIN SHOWN TO BE SUPERIOR COMPARED WITH GLIMEPIRIDE AS ADD ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES

【24h】

THE SGLT2 INHIBITOR CANAGLIFLOZIN SHOWN TO BE SUPERIOR COMPARED WITH GLIMEPIRIDE AS ADD ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES

机译：SGLT2抑制剂卡格非嗪与格列美脲相比具有优越的治疗效果，可用于2型糖尿病患者对二甲双胍的治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Diabetes, obesity & metabolism》 |2016年第9期|共1页
作者
Idris Iskandar;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. THE SGLT2 INHIBITOR CANAGLIFLOZIN SHOWN TO BE SUPERIOR COMPARED WITH GLIMEPIRIDE AS ADD ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES [J] . Idris Iskandar Diabetes, obesity & metabolism . 2016,第9期

机译：SGLT2抑制剂卡格非嗪与格列美脲相比具有优越的治疗效果，可用于2型糖尿病患者对二甲双胍的治疗
2. SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients [J] . André J Scheen Diabetes, metabolic syndrome and obesity: targets and therapy . 2020,第6期

机译：SGLT2抑制剂作为2型糖尿病患者对二甲双胍的加入治疗：亚洲与非亚洲患者的安慰剂对照试验综述
3. Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 diabetes [J] . Zhou Yue, Geng Zhuang, Wang Xiang, Diabetes/metabolism research and reviews . 2020,第2期

机译：荟萃分析SGLT2抑制剂和基于Incetin基剂组合治疗的疗效和安全性与Sglt2i单独或加入2型糖尿病中的二甲双胍
4. Discovery of Novel α-Amylase Inhibitors as Type Two Diabetes Mellitus Therapy through Fragment-Based Drug Design [C] . Muhammad Fauzi Hidayat, Eka Gunarti Ningsih, Ahmad Husein Alkaff International Conference on Science and Technology . 2020

机译：通过碎片的药物设计发现新型α-淀粉酶抑制剂作为两种糖尿病疗法
5. Diabetes Self-Care Management Behaviors and Barriers to Diabetes Care among Patients with Mental Illness and Type 2 Diabetes, Compared to Those with Type 2 Diabetes Only [D] . Olumba, Appolonia Adaku. 2018

机译：糖尿病在精神疾病和2型糖尿病患者中患糖尿病护理的自我保健管理行为和障碍，与2型糖尿病的患者相比
6. Rationale design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin an SGLT2 inhibitor versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control [O] . Martin Ridderstråle, Robbyna Svaerd, Cordula Zeller, 2013

机译：血糖控制不佳的2型糖尿病患者进行SGLT2抑制剂依帕格列净4年（208周）III期试验的理由设计和基线特征与格列美脲联用二甲双胍
7. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control [O] . 2013

机译：血糖控制不佳的2型糖尿病患者进行SGLT2抑制剂依帕格列净4年（208周）III期临床试验的理论，设计和基线特征

THE SGLT2 INHIBITOR CANAGLIFLOZIN SHOWN TO BE SUPERIOR COMPARED WITH GLIMEPIRIDE AS ADD ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES

著录项

相似文献

相关主题

期刊订阅